Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …

A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of pathologically
activated, mostly immature, myeloid cells that exert robust immunosuppressive functions …

Purpose: The successful implementation of immune checkpoint inhibitors (ICI) in the clinical
management of various solid tumors has raised considerable expectations for patients with …

While chemotherapy and radiotherapy remain the first-line approaches for the management
of most unresectable tumors, immunotherapy has emerged in the past two decades as a …

ABSTRACT LTX-315 is a nonameric oncolytic peptide in early clinical development for the
treatment of solid malignancies. Preclinical and clinical evidence indicates that the …

At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to
immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite …

Major advances have been made in precision medicine of breast cancer patients with a
series of molecular targeted therapies now in clinical use or in late clinical development …

The past decades witnessed the clinical employment of targeted therapies including but not
limited to tyrosine kinase inhibitors (TKIs) that restrain a broad variety of pro-tumorigenic …